The Effects of CLA (CLA/9:11) on the Expression of RAGE and sRAGE in THP-1 cells in Type 2 Diabetes
University of Wales Institute Cardiff
MetadataShow full item record
The multi-ligand receptor Receptor for Advanced Glycated End Products, RAGE has been implicated in the pathogenesis of several chronic diseases such as inflammation, atherosclerosis and Diabetes. In Diabetes, hyperglycaemic conditions cause the increased formation of Advanced Glycation End-Products (AGE) which binds to and up-regulate RAGE. The soluble form of RAGE that exists, sRAGE, a product of alternate splicing or cleavage of membrane bound RAGE has been found to act as a decoy receptor for the interaction between RAGE and its pro-inflammatory ligands (AGEs), reducing diabetic impairment of vascular injury in many studies. RAGE and pro-inflammatory cytokine production is modulated by NF-κB, a Nuclear Transcription factor. Peroxisome Proliferator-Activated Receptors, PPAR-γ activation by its ligands (Thiazolidinediones and Dietary Conjugated Linoleic Acid) have been shown to inhibit NF-κB activation in some studies. The aim of this investigation is to investigate the effects that incubation with CLA/9:11 at different Concentrations (20µm/100µM) and different incubation times (1, 4,24,48,72 hours) has on expression of sRAGE in THP-1 cells using Western Immunoblotting as a means of analysis. All Western Blots failed and therefore we are unable to determine what effects, if any CLA/9:11 has on expression of sRAGE in THP-1 Cells.